Searchable abstracts of presentations at key conferences in endocrinology

ea0021p332 | Steroids | SFEBES2009

Steroid analysis in patients receiving metyrapone therapy

Owen Laura , Halsall David , Yates Alexandra , Keevil Brian

Clinical guidance recommends titrating the dose of metyrapone against serum cortisol concentrations. These serum samples are usually measured by immunoassays; however it has been well documented that there are interferences in these assays in patients with altered steroid metabolism due to a pathological process or drug treatment. The increasing availability of mass spectrometry (MS) assays for steroid hormones may circumvent this issue and assays that measure multiple steroid...

ea0021p333 | Steroids | SFEBES2009

Reference range data on androsterone glucuronide in healthy male and female volunteers and clinical uses of the assay

Adaway Joanne , Miller Adrian , Wu F C W , Keevil Brian

Androsterone glucuronide (ADG) is a major metabolite of the androgen dihydrotestosterone and has also been shown to arise from the intracrine conversion of other adrenal androgens such as androstenedione and androsterone. ADG has been shown to be raised in some women with clinical signs of hyperandrogenism such as acne and hirsutism, even when levels of androgens, e.g. testosterone or DHEA-S are normal. This indicates that raised ADG levels may be an early indication of hypera...

ea0021p337 | Steroids | SFEBES2009

Determination of tandem mass spectrometry specific reference ranges for testosterone, androstenedione and DHEAS

Macdonald Philip , Wu Frederick , Owen Laura , Keevil Brian

Testosterone, androstenedione and DHEAS are commonly measured by immunoassays. Variations in antibody specificity and calibration of assays results in non-commutability of measurements. Even more specific mass spectrometry (LC–MS/MS) assays still exhibit differences in calibration. As the use of mass spectrometry for measuring steroids is becoming more common in the clinical laboratory, the development of LC–MS/MS reference ranges for these analytes is essential to h...

ea0020p208 | Endocrine tumours and neoplasia | ECE2009

Laboratory diagnosis of gastrinoma remains difficult

Ardill Joy , Armstrong Lee , McCance David , Johnston Brian

Before the use of potent acid suppressing drugs and in particular proton pump inhibiters (PPI), most patients with gastrinoma presented with Zollinger–Ellison syndrome and diagnosis was problematic in only a few. In recent years, the syndrome is rarely seen and gastrinoma patients present with less overt symptoms and hypergastrinaemia which may be mild. Increasingly patients present later.In the population, hypergastrinaemia most commonly occurs bec...

ea0020p297 | Clinical case reports and clinical reports | ECE2009

Sustained response to interferon α in a patient with an advanced metastatic serotonin secreting endocrine tumour – case report

Ardill Joy , Johnston Brian , McCance David , Eatock Martin

This 52-year-old lady presented in 2001 at a GI clinic complaining of occasional abdominal cramps, which could be severe and prolonged. Her symptoms were not associated with diarrhoea or constipation. Weight loss of 4.5 kg over 4 months was noted. Coeliac disease was excluded and a diagnosis of severe irritable bowel was made.In January 2002 she returned to the clinic with further weight loss (total 8 kg), cyclical symptoms of diarrhoea lasting 3–5 ...

ea0015oc3 | Young Endocrinologist prize session | SFEBES2008

Does 11βHSD1 in visceral adipose tissue (VAT) deliver cortisol to the liver? Studies with portal vein sampling and tracer infusion in humans

Stimson Roland , Andrew Ruth , Redhead Doris , Hayes Peter , Walker Brian

Cortisol is regenerated from cortisone by 11βHSD1 reductase in cells from VAT. Mice overexpressing 11βHSD1 in adipocytes have more glucocorticoids in the portal vein (PV) and hepatic insulin resistance. In humans, hepatic vein (HV) sampling during D4-cortisol tracer infusion confirmed substantial splanchnic cortisol generation, and indirect modelling suggested major contributions from both liver and VAT. PV sampling in dogs, however, did not reveal cortisol release f...

ea0015p100 | Clinical practice/governance and case reports | SFEBES2008

Vasoactive intestinal polypeptide secreting pancreatic tumour (VIPoma) with liver metastases in a 46-year-old male, long term survival after orthotopic liver transplantation

Johnston Philip , Ardill Joy , Johnston Brian , Mc Cance David

A 46-year-old male presented in 1981 with a 2 year history of profuse watery diarrhoea, three stone weight loss and fatigue. On examination he appeared gaunt with diffuse muscle weakness. Investigations revealed hypokalaemia (2.5 mmol/l; NR 3.5–4.5), achlorhydria and a raised vasoactive intestinal polypeptide (VIP) (1500ng/L; NR 0–100). Abdominal CT showed a 5 cm pancreatic mass but with no focal liver pathology. A distal pancreatectomy was performed. Histology confi...

ea0015p313 | Steroids | SFEBES2008

Measurement of salivary cortisol with LC-MS/MS in patients with suspected adrenal pathology

Perogamvros Ilias , Keevil Brian , Owen Laura , Trainer Peter , Brabant Georg

Salivary cortisol (SalC) potentially has advantages over serum cortisol (SerC) as it is easier to collect and possibly reflects unbound (free) cortisol. SalC levels are approximately 10 times lower than SerC and require high measurement precision best addressed by liquid chromatography–tandem mass spectrometry (LC-MS/MS), which in contrast to previously used radioimmunoassays eliminates cross-reactivity by other steroids. We describe the use of LC-MS/MS to evaluate the po...

ea0013p11 | Bone | SFEBES2007

Alendronate accelerates increases in bone mineral density with growth hormone replacement but may attenuate the anabolic effect of growth gormone replacement on bone in adult growth hormone deficiency

White Helen , Ahmad Aftab , Durham Brian , Fraser William , Vora Jiten

Introduction: Adult Growth Hormone Deficiency (AGHD) is associated with osteoporosis. Underlying mechanisms involved in the pathogenesis include reduced target-organ sensitivity to the effect of PTH. Growth Hormone Replacement (GHR) in AGHD leads to increased PTH target-organ sensitivity and consequently increased bone turnover and bone mineral density (BMD).Aims: We determined the effect of alendronate, given in addition to GHR, on PTH target-organ sens...

ea0013p73 | Clinical practice/governance and case reports | SFEBES2007

Recurrent hypoglycaemia caused by metastatic insulinoma in a patient with Type 2 diabetes

Sandeep Thekkepat , Hughes Kate , Adamson Karen , Patrick Alan , Frier Brian

Insulinoma is a rare tumour, but is the commonest cause of hyperinsulinaemic hypoglycaemia in adults. It is characterised by symptomatic hypoglycaemia with inappropriately elevated plasma insulin and C-peptide levels. 10% of insulinomas are malignant. The coexistence of insulinoma with diabetes mellitus is extremely rare with only 20 previously reported cases. This can therefore pose a diagnostic challenge.An 83 year old man, who developed Type 2 diabete...